Alternative normalization methods demonstrate widespread cortical hypometabolism in untreated de novo Parkinson's disease

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 3, 2012, Pages 299-308

  Berti, V ^a   Polito, C ^a   Borghammer, P ^b   Ramat, S ^a   Mosconi, L ^c   Vanzi, E ^a   De Cristofaro, M T ^a   De Leon, M ^c   Sorbi, S ^a   Pupi, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluorodeoxyglucose F18; Parkinson disease; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FRONTAL CORTEX; GRAY MATTER; GRAY MATTER NORMALIZATION; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; MALE; METABOLIC DISORDER; OCCIPITAL CORTEX; PARIETAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; TEMPORAL CORTEX; VOXEL BASED MORPHOMETRY; WHITE MATTER; WHITE MATTER NORMALIZATION; YAKUSHEV NORMALIZATION;

AGED; CASE-CONTROL STUDIES; CEREBRAL CORTEX; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84865311872     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801.
2. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912-21.
3. Borghammer P, Cumming P, Aanerud J, Gjedde A. Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease. Neuroimage 2009;45:249-57.
4. Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowiak RS. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab 1990;19:458-66.
5. Wang GJ, Volkow ND, Wolf AP, Brodie JD, Hitzemann RJ. Intersubject variability of brain glucose metabolic measurements in young normal males. J Nucl Med 1994;35:1457-66.
6. Berding G, Odin P, Brooks DJ, Nikkhah G, Matthies C, Peschel T et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [18F]FDG-PET. Mov Disord 2001;16:1014-22.
7. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999:52:541-6.
8. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbè C, Cunningham VJ et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 2000;123:340-52.
9. Borghammer P, Chakravarty M, Jonsdottir KY, Sato N, Matsuda H, Ito K et al. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct Funct 2010;214:303-17.
10. Borghammer P, Jonsdottir KY, Cumming P, Ostergaard K, Vang K, Ashkanian M et al. Normalization in PET group comparison studies - The importance of a valid reference region. Neuroimage 2008;40:529-40.
11. Yakushev I, Hammers A, Fellgiebel A, Schnidtmann I, Scheurich A, Bchholz HG et al. SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage 2009;44:43-50.
12. Borghammer P, Aanerud J, Gjedde A. Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization. Neuroimage 2009;46:981-8.
13. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007;130:1834-46.
14. Ghaemi M, Raethjen J, Hilker R, Rudolf J, Sobesky J, Deuschl G et al. Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study. Mov Disord 2002;17:782-8.
15. Ma Y, Tang C, Moeller JR, Eidelberg D. Abnormal regional brain function in Parkinson's disease: truth or fiction? Neuroimage 2009;45:260-6.
16. Berti V, Polito C, Ramat S, Vanzi E, De Cristofaro MT, Pellicanò G et al. Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging 2010;37:537-44.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
18. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
19. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Mardsen CD, Calne DB, Goldstein M, eds. Recent development in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare information; 1987:153-64.
20. Schwartzman RJ, Alexander GM. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease. Brain Res 1985;358:137-43.
21. Bezard E, Crossman AR, Gross CE, Brotchie JM. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J 2001;15:1092-4.
22. Casteels C, Lauwers E, Bormans G, Baekelandt V, Van Laere K. Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease. Eur J Nucl Med Mol Imaging 2008;35:124-34.
23. Borghammer P, Cumming P, Aanerud J, Forster S, Gjedde A. Subcortical elevation of metabolism in Parkinson's disease - a critical reappraisal in the context of global mean normalization. Neuroimage 2009;47:1514-21.
24. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003;19:1233-9.
25. Worsley KJ, Marret S, Neelin P, Vandal AC, Friston KJ, Evans AC. A unified statistical approach for determining significant signals in images of cerebral activation. Hum Brain Mapp 1996;4:58-73.
26. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York, NY: Thieme Medical Publishers, Inc.; 1988.
27. Lancaster JL, Summerln JL, Rainey L, Freitas CS, Fox PT. The Talairach Daemon, a database server for Talairach Atlas labels. Neuroimage 1997;5:s633.
28. Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 2000;10:120-31.
29. Imon Y, Matsuda H, Ogawa M, Kogure D, Sunohara N. SPECT image analysis using statistical parametric mapping in patients with Parkinson's disease. J Nucl Med 1999;40:1583-9.
30. Melzer TR, Watts R, MacAskill MR, Pearson JF, Rüeger S, Pitcher TL et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain 2011;134:845-55.
31. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson's disease dementia in vivo. Neurology 2010;74:885-92.
32. Van Laere K, Santens P, Bosman T, De Reuck J, Mortelmans L, Dierckx R. Statistical parametric mapping of (99m)Tc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters. J Nucl Med 2004;45:933-42.
33. Mito Y, Yoshida K, Yabe I, Makino K, Hirotani M, Tashiro K et al. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease. Clin Neurol Neurosurg 2005;107:396-403.
34. Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieres P, Antonini A et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 1999;40:1264-9.
35. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301.
36. Obeso JA, Marin C, Rodriguez-Oroz C, Blesa J, Benitez-Temino B, Mena-Segovia J et al. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol 2008;64:S30-S46.
37. Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009;73:273-8.
38. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-16.